Hepatolithiasis: clinical series, review and current management strategy
Executive Summary
Hepatolithiasis (HL), characterized by the presence of stones in the intrahepatic bile ducts, remains a significant clinical challenge due to its local and systemic complications, high recurrence rates, and insufficient standardized treatment modalities. Historically prevalent in East Asia, global incidence is rising due to migration, while westernization of diets in the East is paradoxically causing a decrease in those regions.
Effective management requires a multimodal, multidisciplinary approach involving endoscopy, radiology, and surgery. While minimally invasive endoscopic and radiological interventions are preferred as first-line treatments, surgical options—ranging from segment resection to liver transplantation—are necessary for complex cases involving biliary strictures, liver atrophy, or suspected malignancy. A critical concern is the progression to intrahepatic cholangiocarcinoma (ICCA), for which HL is considered a precancerous condition. Prevention of cholangitis, correction of strictures, and functional biliary reconstruction (particularly Roux-en-Y hepaticojejunostomy) are paramount to improving patient outcomes and quality of life.
1. Overview and Epidemiology
Primary hepatolithiasis, also known as "oriental cholangiohepatitis," refers to the formation of stones within the intrahepatic bile ducts proximal to the bifurcation of the common bile duct.
Geographic Variation: The incidence is highest in East Asian countries, accounting for approximately 25% of gallstone cases in Taiwan, 15% in Hong Kong, and 4% in Japan.
Global Trends: In Western countries, the incidence is roughly 1%, though it is increasing due to global migration patterns (from 0.32/100,000 to 0.85/100,000 over the last three decades).
Dietary Factors: Interestingly, the incidence is decreasing in Eastern countries as diets become more "Westernized."
2. Etiology and Predisposing Factors
While the exact etiology is unknown, several factors contribute to the development of HL:
Primary Factors: Cholestasis, biliary strictures (often post-surgical), infection, and anatomical anomalies.
Biological/Genetic Factors: Disorders in bile metabolism, genetic mutations, and ethnic differences.
Inflammatory Mechanisms: Lipopolysaccharides induce endogenous beta-glucuronidase and c-myc release from hepatocytes and biliary epithelium, contributing to pigment stone formation.
Infections: In East Asia, parasitic infestations (e.g., Clonorchis sinensis from raw fish consumption) are responsible for 30% of cases.
3. Classification Systems
Various systems categorize the severity and type of HL to guide treatment:
4. Diagnostic Modalities
Most cases (85%) are diagnosed via preoperative imaging, while 15% are identified during surgery or endoscopic procedures.
Primary Screening: Ultrasound (US) and Computed Tomography (CT) are the first choices, diagnosing 66–87% of cases. US identifies stone size and characteristics, while CT identifies dilated ducts and strictures.
Advanced Imaging:
MRCP/MRI: Highly beneficial for detecting and localizing stones and differentiating intraductal lesions.
EUS/IDUS: Provide detailed information on stenosis.
PET-CT: Utilized for diagnosing HL-induced ICCA and distant metastases.
Direct Visualization: Cholangiography and cholangioscopy are superior for detecting bile duct strictures.
5. Clinical Study Analysis (2014–2019)
A retrospective study of 17 patients (mean age 64.3) provided insights into current management outcomes:
Patient Profiles: Most (70.5%) were Grade III (Japanese classification). Seven had previous cholecystectomies.
Surgical Findings: Nine patients required surgery. Left hepatectomy and lateral sector resection were performed in four cases. Anastomotic stenosis (often from previous biliary surgery) was a major driver for HL.
Nonoperative Management: Eight patients were followed with medical or endoscopic approaches. Recurrent cholangitis was the most common complication in this group.
Outcomes: No postoperative mortality was recorded. One 89-year-old nonoperative patient died of sepsis. The mean follow-up was 43 months, with no recurrences in the surgical group.
6. Management Strategies
Medical Treatment
Limitations: Generally insufficient for pigment-rich stones.
Ursodeoxycholic Acid (UDCA): Recommended for cholesterol stones (15% of cases), Caroli syndrome, or preventing relapse in patients with MDR3 deficiency. Some studies suggest it may help prevent the development of ICCA.
Endoscopic and Radiological Interventions
First-Line Approach: ERCP and PTC are used to remove stones via balloon dilatation, sphincterotomy, or lithotripsy (pneumatic, laser, etc.).
Stricture Management: Balloon or bougie dilatation and stenting are employed for stubborn stenosis.
Biliary Drainage: Percutaneous transhepatic biliary drainage (PTBD) is effective for opening strictures and stone extraction through flushing techniques.
Surgical Intervention
Surgery is indicated for failed endoscopic interventions, recurrent cholangitis, liver atrophy, or suspicion of malignancy.
Hepatectomy: The most effective treatment for localized disease as it removes the stenotic area and associated stones. Laparoscopic hepatectomy is preferred for left-lobe or lateral sector cases.
Anastomosis Revision: Necessary for patients with stenosis following past operations (e.g., Whipple procedure or biliary trauma reconstructions).
Liver Transplantation: The only option for terminal cases resulting in liver failure.
7. Complications and Prognosis
Untreated or recurrent HL can lead to lethal outcomes:
Biliary Cirrhosis: Develops due to recurrent cholestasis and ductal fibrosis, affecting 3.7%–14.1% of patients.
Intrahepatic Cholangiocarcinoma (ICCA): HL is a precancerous lesion; 3.3%–21.2% of patients develop ICCA.
Risk Factors for Cancer: Liver atrophy, high CA 19-9 levels, left-sided HL, and bilateral stones.
Surgical Prognosis: Curative resection (R0) provides 5-year survival rates of approximately 50%, though survival drops significantly in lymph node-positive cases.
Key Clinical Conclusions
Functional Reconstruction: Hepaticojejunostomies should be performed in a Roux-en-Y style to prevent biliary reflux.
Multidisciplinary Necessity: Management requires close coordination between surgeons, radiologists, and gastroenterologists.
Surgical Priority: Resection should be the primary choice in cases of liver atrophy, abscesses, or suspected ICCA to prevent severe morbidity.
